这项研究的目的是鉴定一种双歧杆菌菌株,该菌株可改善罗伊氏LimosilactobacillusDSM17938的性能。初步测试表明,长双歧杆菌亚种。长菌株在体内样条件下促进了DSM17938的生长。进一步的表征显示,其中一个菌株,BG-L47与BG-L48相比具有更好的胆汁和酸耐受性,以及与BG-L48和对照菌株BB536相比具有更好的粘液粘附性。BG-L47还具有代谢多种碳水化合物和糖醇的能力。BG-L47和BB536的糖苷水解酶(GH)基因的定位揭示了许多与植物纤维利用相关的GH。然而,BG-L47具有更广泛的表型纤维利用能力。此外,B.长子。长细胞增强了共培养过程中罗伊氏乳杆菌DSM17938产生的细胞外膜囊泡(MV)的生物活性。分泌型5'-核苷酸酶(5'NT),一种将AMP转化为信号分子腺苷的酶,BG-L47增强的MV增加。MV对疼痛受体瞬时受体电位香草素1(TRPV1)发挥了改善的拮抗作用,并增加了外周血单核细胞(PBMC)模型中免疫发育标志物IL-6和IL-1β的表达。最后,通过基因组安全性评估和人体安全性研究评估了BG-L47的安全性.微生物群分析显示,该处理没有引起组合物的显著变化。总之,B.长子。长BG-L47具有良好的生理特性,可以提高罗伊乳杆菌DSM17938的体外活性,并且可以安全食用,使其成为益生菌研究中进一步评估的候选人。
目的:通过使用包含具有协同特性的菌株组合的益生菌,与宿主实现有益相互作用的可能性可以增加。在这项研究中,我们首先对长双歧杆菌亚种进行了广泛的筛选。长菌株在协同潜力和生理特性方面。我们确定了一个优良的菌株,BG-L47,具有良好的特性和增强已知益生菌菌株罗伊氏LimosilactobacillusDSM17938活性的潜力。此外,在一项人体随机临床研究中,通过进行基因组安全性评估,我们证明了BG-L47是安全的.这项工作说明了细菌-细菌相互作用在菌株水平上有所不同,并进一步提供了寻找和选择益生菌伴侣菌株的策略。
The aim of this study was to identify a Bifidobacterium strain that improves the performance of Limosilactobacillus reuteri DSM 17938. Initial tests showed that Bifidobacterium longum subsp. longum strains boosted the growth of DSM 17938 during in vivo-like conditions. Further characterization revealed that one of the strains, BG-L47, had better bile and acid tolerance compared to BG-L48, as well as mucus adhesion compared to both BG-L48 and the control strain BB536. BG-L47 also had the capacity to metabolize a broad range of carbohydrates and sugar alcohols. Mapping of glycoside hydrolase (GH) genes of BG-L47 and BB536 revealed many GHs associated with plant-fiber utilization. However, BG-L47 had a broader phenotypic fiber utilization capacity. In addition, B. longum subsp. longum cells boosted the bioactivity of extracellular membrane vesicles (MV) produced by L. reuteri DSM 17938 during co-cultivation. Secreted 5\'-nucleotidase (5\'NT), an enzyme that converts AMP into the signal molecule adenosine, was increased in MV boosted by BG-L47. The MV exerted an improved antagonistic effect on the pain receptor transient receptor potential vanilloid 1 (TRPV1) and increased the expression of the immune development markers IL-6 and IL-1ß in a peripheral blood mononuclear cell (PBMC) model. Finally, the safety of BG-L47 was evaluated both by genome safety assessment and in a human safety study. Microbiota analysis showed that the treatment did not induce significant changes in the composition. In conclusion, B. longum subsp. longum BG-L47 has favorable physiological properties, can boost the in vitro activity of L. reuteri DSM 17938, and is safe for consumption, making it a candidate for further evaluation in probiotic studies.
OBJECTIVE: By using probiotics that contain a combination of strains with synergistic properties, the likelihood of achieving beneficial interactions with the host can increase. In this study, we first performed a broad screening of Bifidobacterium longum subsp. longum strains in terms of synergistic potential and physiological properties. We identified a superior strain, BG-L47, with favorable characteristics and potential to boost the activity of the known probiotic strain Limosilactobacillus reuteri DSM 17938. Furthermore, we demonstrated that BG-L47 is safe for consumption in a human randomized clinical study and by performing a genome safety assessment. This work illustrates that bacteria-bacteria interactions differ at the strain level and further provides a strategy for finding and selecting companion strains of probiotics.